Ad is loading...
GMAB
Price
$20.59
Change
-$0.59 (-2.79%)
Updated
Nov 15 closing price
87 days until earnings call
VIR
Price
$8.01
Change
-$0.63 (-7.29%)
Updated
Nov 15 closing price
95 days until earnings call
Ad is loading...

GMAB vs VIR

Header iconGMAB vs VIR Comparison
Open Charts GMAB vs VIRBanner chart's image
Genmab A/S ADS
Price$20.59
Change-$0.59 (-2.79%)
Volume$1.31M
CapitalizationN/A
Vir Biotechnology
Price$8.01
Change-$0.63 (-7.29%)
Volume$1.48M
CapitalizationN/A
GMAB vs VIR Comparison Chart
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VIR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
GMAB vs. VIR commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Sell and VIR is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (GMAB: $20.59 vs. VIR: $8.01)
Brand notoriety: GMAB and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 113% vs. VIR: 144%
Market capitalization -- GMAB: $13.65B vs. VIR: $1.1B
GMAB [@Biotechnology] is valued at $13.65B. VIR’s [@Biotechnology] market capitalization is $1.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileVIR’s FA Score has 0 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • VIR’s FA Score: 0 green, 5 red.
According to our system of comparison, VIR is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 3 bullish TA indicator(s).

  • GMAB’s TA Score: 4 bullish, 4 bearish.
  • VIR’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, GMAB is a better buy in the short-term than VIR.

Price Growth

GMAB (@Biotechnology) experienced а -10.79% price change this week, while VIR (@Biotechnology) price change was -16.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

GMAB is expected to report earnings on Feb 12, 2025.

VIR is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($13.7B) has a higher market cap than VIR($1.1B). VIR YTD gains are higher at: -20.378 vs. GMAB (-35.333). GMAB has higher annual earnings (EBITDA): 7.88B vs. VIR (-525.76M). GMAB has more cash in the bank: 15.7B vs. VIR (1.15B). VIR has less debt than GMAB: VIR (115M) vs GMAB (1.02B). GMAB has higher revenues than VIR: GMAB (19B) vs VIR (57.6M).
GMABVIRGMAB / VIR
Capitalization13.7B1.1B1,242%
EBITDA7.88B-525.76M-1,500%
Gain YTD-35.333-20.378173%
P/E Ratio20.10N/A-
Revenue19B57.6M32,986%
Total Cash15.7B1.15B1,364%
Total Debt1.02B115M886%
FUNDAMENTALS RATINGS
GMAB: Fundamental Ratings
GMAB
OUTLOOK RATING
1..100
61
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
49
PRICE GROWTH RATING
1..100
84
P/E GROWTH RATING
1..100
92
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GMABVIR
RSI
ODDS (%)
Bullish Trend 3 days ago
58%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
58%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
69%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 14 days ago
65%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
56%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
67%
N/A
View a ticker or compare two or three
Ad is loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VIR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SMUYX9.95-0.02
-0.20%
SEI Multi-Strategy Alternative Y (SIMT)
RYMMX64.25-0.35
-0.54%
Rydex S&P MidCap 400 Pure Value C
RGLJX23.70-0.25
-1.04%
American Funds Global Insight R-5E
MSGSX16.85-0.27
-1.58%
MassMutual Small Cap Gr Eq R5
IEOHX17.70-0.44
-2.43%
Voya Large Cap Growth Port I

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-2.79%
GNMSF - GMAB
58%
Loosely correlated
-3.53%
AXON - GMAB
47%
Loosely correlated
-0.86%
VIR - GMAB
43%
Loosely correlated
-7.29%
CRSP - GMAB
38%
Loosely correlated
+0.85%
PRME - GMAB
37%
Loosely correlated
-6.95%
More

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been loosely correlated with ADPT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
-7.29%
ADPT - VIR
52%
Loosely correlated
-8.96%
CRSP - VIR
51%
Loosely correlated
+0.85%
TECH - VIR
49%
Loosely correlated
-6.85%
NTLA - VIR
48%
Loosely correlated
-7.61%
AVIR - VIR
48%
Loosely correlated
-2.72%
More